| Abstract | Although topical antibiotics have been considered less than effective agents in the treatment of "impetigo," recent experience suggests that topical therapy has a place as primary treatment of pyoderma and impetigo. This bacteriologically controlled, randomized study compared the safety and efficacy of mupirocin with oral erythromycin in the treatment of pyoderma and impetigo. A total of 29 mupirocin-treated and 30 erythromycin-treated patients completed the study. None of the mupirocin-treated patients reported adverse experiences compared with 4 erythromycin-treated patients who reported 6 adverse experiences. The mupirocin-treated group had a significantly higher benefit:risk ratio than the erythromycin-treated group as measured by the investigator's global evaluation (P = 0.01). Both treatments eradicated 100% of the two most common pathogens, Staphylococcus aureus and Streptococcus pyogenes. Results from this study demonstrate that mupirocin is as effective as systemic erythromycin ethylsuccinate for treatment of pyoderma and impetigo. |
| Authors | S McLinn
(Affiliation: Scottsdale Pediatrics, AZ 85251.)
|
| Journal | The Pediatric infectious disease journal
(Pediatr Infect Dis J)
Vol. 7
Issue 11
Pg. 785-90
(Nov 1988)
ISSN: 0891-3668 UNITED STATES |
| PMID | 3148127
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
| Chemical References |
- Anti-Bacterial Agents
- Fatty Acids
- Erythromycin
- Mupirocin
|
| Topics |
- Administration, Topical
- Anti-Bacterial Agents
(administration & dosage, therapeutic use)
- Erythromycin
(therapeutic use)
- Evaluation Studies as Topic
- Fatty Acids
(administration & dosage, therapeutic use)
- Humans
- Infant
- Mupirocin
- Pyoderma
(diagnosis, drug therapy, etiology)
|
